NASDAQ:CDNA CareDx (CDNA) Stock Price, News & Analysis $19.01 +0.14 (+0.74%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$18.06▼$19.3750-Day Range$13.01▼$19.0052-Week Range$4.80▼$19.58Volume1.20 million shsAverage Volume862,325 shsMarket Capitalization$990.04 millionP/E RatioN/ADividend YieldN/APrice Target$17.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get CareDx alerts: Email Address CareDx MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside10.6% Downside$17.00 Price TargetShort InterestBearish8.04% of Float Sold ShortDividend StrengthN/ASustainability-0.66Upright™ Environmental ScoreNews Sentiment0.83Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.49) to ($1.34) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.51 out of 5 starsMedical Sector522nd out of 936 stocksMedical Laboratories Industry13th out of 18 stocks 2.3 Analyst's Opinion Consensus RatingCareDx has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageCareDx has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about CareDx's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.04% of the float of CareDx has been sold short.Short Interest Ratio / Days to CoverCareDx has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in CareDx has recently increased by 2.62%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCareDx does not currently pay a dividend.Dividend GrowthCareDx does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCareDx has received a 61.52% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "DNA sequencers", "Genomics analysis tools", and "Patient flow management systems" products. See details.Environmental SustainabilityThe Environmental Impact score for CareDx is -0.66. Previous Next 2.7 News and Social Media Coverage News SentimentCareDx has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for CareDx this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for CDNA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added CareDx to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CareDx insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.20% of the stock of CareDx is held by insiders.Read more about CareDx's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for CareDx are expected to grow in the coming year, from ($1.49) to ($1.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CareDx is -5.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CareDx is -5.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCareDx has a P/B Ratio of 3.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about CareDx's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. About CareDx Stock (NASDAQ:CDNA)CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.Read More CDNA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CDNA Stock News HeadlinesJuly 25 at 6:21 AM | americanbankingnews.comCareDx (NASDAQ:CDNA) Reaches New 52-Week High at $19.54July 24 at 7:26 AM | americanbankingnews.comCareDx (CDNA) Scheduled to Post Quarterly Earnings on WednesdayJuly 26, 2024 | Porter & Company (Ad)We recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…July 19, 2024 | markets.businessinsider.comWhere CareDx Stands With AnalystsJuly 19, 2024 | americanbankingnews.comCareDx (NASDAQ:CDNA) Shares Gap Down to $18.57July 18, 2024 | americanbankingnews.comCareDx (NASDAQ:CDNA) Price Target Raised to $16.00 at The Goldman Sachs GroupJuly 16, 2024 | prnewswire.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of CareDx, Inc. (NASDAQ: CDNA)July 15, 2024 | seekingalpha.comCareDx: Benefiting From Some CertaintyJuly 26, 2024 | Porter & Company (Ad)We recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…June 3, 2024 | businesswire.comLandmark Independent Publication in Nature Medicine Validates CareDx AlloView AI-Enabled Risk Prediction Model and Demonstrates AlloSure Kidney Detects Subclinical Rejection in Stable PatientsMay 30, 2024 | businesswire.comAI Integration and Real-World Utility of CareDx Portfolio Highlighted in New Data at the 2024 American Transplant CongressMay 29, 2024 | finance.yahoo.comCareDx Reiterates Position that it Does Not Infringe the ‘544 Patent, Injunction Motion is IrrelevantMay 29, 2024 | businesswire.comCareDx to Participate in Upcoming Investor ConferencesMay 25, 2024 | finance.yahoo.comCareDx, Inc (CDNA)May 16, 2024 | finance.yahoo.comLandmark Study Shows CareDx’s HeartCare Outperforms dd-cfDNA Alone in Identifying Rejection and Patients Experienced Excellent Outcomes with Fewer BiopsiesMay 16, 2024 | businesswire.comLandmark Study Shows CareDx's HeartCare Outperforms dd-cfDNA Alone in Identifying Rejection and Patients Experienced Excellent Outcomes with Fewer BiopsiesMay 15, 2024 | markets.businessinsider.comMaintaining Hold on CareDx Amid Growth, Valuation, and Uncertainty ConcernsMay 15, 2024 | markets.businessinsider.comBalanced Outlook for CareDx: Strong Performance Amid Rising CompetitionSee More Headlines Receive CDNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CareDx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Confirmed)7/31/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNASDAQ:CDNA CUSIPN/A CIK1217234 Webwww.caredxinc.com Phone(415) 287-2300Fax415-287-2450Employees635Year FoundedN/APrice Target and Rating Average Stock Price Target$17.00 High Stock Price Target$22.00 Low Stock Price Target$12.00 Potential Upside/Downside-10.6%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($3.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-190,280,000.00 Net Margins-66.59% Pretax Margin-66.61% Return on Equity-55.08% Return on Assets-37.48% Debt Debt-to-Equity RatioN/A Current Ratio4.32 Quick Ratio4.03 Sales & Book Value Annual Sales$280.32 million Price / Sales3.53 Cash FlowN/A Price / Cash FlowN/A Book Value$4.83 per share Price / Book3.94Miscellaneous Outstanding Shares52,080,000Free Float49,896,000Market Cap$990.04 million OptionableOptionable Beta1.78 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Abhishek Jain (Age 47)CFO & Principal Accounting Officer Comp: $425.58kDr. Peter Maag Ph.D. (Age 57)Executive Director Comp: $43.23kMr. Alexander L. Johnson (Age 50)President of Patient & Testing Services Comp: $547.43kMr. John Walter Hanna Jr. (Age 44)President, CEO & Director Ms. Marica Grskovic Ph.D.Chief Operating OfficerDr. Robert N. Woodward Ph.D.Chief Scientific OfficerMr. GS JhaSenior VP, Chief Information Officer & Chief Information Security OfficerJeffrey A. NovackGeneral CounselMs. Stacey FollonSenior VP & Head of Human ResourcesMr. Kashif RathoreChief of Patient & Digital SolutionsMore ExecutivesKey CompetitorsGenetronNASDAQ:GTHGuardant HealthNASDAQ:GHFortreaNASDAQ:FTREVeracyteNASDAQ:VCYTViridian TherapeuticsNASDAQ:VRDNView All CompetitorsInsiders & InstitutionsARK Investment Management LLCSold 161,695 shares on 7/26/2024Ownership: 10.949%Bank of New York Mellon CorpBought 12,404 shares on 7/26/2024Ownership: 0.372%Allspring Global Investments Holdings LLCBought 2,503 shares on 7/26/2024Ownership: 0.041%Sumitomo Mitsui Trust Holdings Inc.Sold 172,077 shares on 7/19/2024Ownership: 4.946%Assenagon Asset Management S.A.Sold 190,268 shares on 7/18/2024Ownership: 0.319%View All Insider TransactionsView All Institutional Transactions CDNA Stock Analysis - Frequently Asked Questions How have CDNA shares performed this year? CareDx's stock was trading at $12.00 at the beginning of 2024. Since then, CDNA stock has increased by 58.4% and is now trading at $19.01. View the best growth stocks for 2024 here. How were CareDx's earnings last quarter? CareDx, Inc (NASDAQ:CDNA) released its quarterly earnings data on Thursday, May, 9th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.46) by $0.18. The business earned $72.05 million during the quarter, compared to the consensus estimate of $63.63 million. CareDx had a negative trailing twelve-month return on equity of 55.08% and a negative net margin of 66.59%. Who are CareDx's major shareholders? CareDx's top institutional investors include ARK Investment Management LLC (10.95%), Sumitomo Mitsui Trust Holdings Inc. (4.95%), Bank of New York Mellon Corp (0.37%) and Assenagon Asset Management S.A. (0.32%). Insiders that own company stock include Reginald Seeto, Peter Maag, Michael Goldberg, Grace Colon, Ankur Dhingra and George Bickerstaff. View institutional ownership trends. How do I buy shares of CareDx? Shares of CDNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of CareDx own? Based on aggregate information from My MarketBeat watchlists, some other companies that CareDx investors own include Block (SQ), Roku (ROKU), Exact Sciences (EXAS), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA) and Enphase Energy (ENPH). This page (NASDAQ:CDNA) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CareDx, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share CareDx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
